These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6962612)

  • 1. Determination of factor X and heparin with chromogenic substrate.
    Aiach M; Michaud A; Capron L; Fiessinger JN
    Acta Chir Scand Suppl; 1982; 509():109-13. PubMed ID: 6962612
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chromogenic substrates for determining coagulation factor X and their use in clinical practice (review of the literature)].
    Bol'shakova TD; Iakunin GA; Smolianitskiĭ AIa
    Lab Delo; 1985; (11):643-8. PubMed ID: 2417012
    [No Abstract]   [Full Text] [Related]  

  • 3. Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders.
    Walenga J; Fareed J; Bermes EW
    Semin Thromb Hemost; 1983 Jul; 9(3):172-93. PubMed ID: 6351253
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monitoring anticoagulant treatment with the KEM-O-MAT 2HP autoanalyzer].
    Laharrague P; Leleu T; Poignot JL; Cambus JP; Biermé R
    Nouv Rev Fr Hematol (1978); 1983; 25(2):107-12. PubMed ID: 6866753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin therapy and monitoring: a role for the chromogenic antifactor Xa assay.
    Rosén S; Casoni MC
    Am Clin Lab; 2001 Aug; 20(7):35-8. PubMed ID: 11570272
    [No Abstract]   [Full Text] [Related]  

  • 6. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer.
    Aiach M; Léon M; Michaud A; Capron L
    Semin Thromb Hemost; 1983 Jul; 9(3):206-16. PubMed ID: 6351255
    [No Abstract]   [Full Text] [Related]  

  • 7. Coacute heparin: a new simple monotest for monitoring heparin treatment.
    Friberger P; Urig E; Eriksson-Skoog L; Svensson S; Isacson C
    Semin Thromb Hemost; 1994; 20(4):328-32. PubMed ID: 7899863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of an automated amidolytic factor X assay in oral anticoagulant treatment.
    van Wijk EM; Jeletich A; ten Cate JW
    Acta Chir Scand Suppl; 1982; 509():117-22. PubMed ID: 6962614
    [No Abstract]   [Full Text] [Related]  

  • 9. Development and characterization of an automated assay of effective heparin activity in plasma.
    Pierson-Perry JF; Obzansky DM; Mizzer JP
    Clin Chem; 1987 Sep; 33(9):1630-4. PubMed ID: 3621562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex].
    Sampol J; Rossi JM; Lejay G
    Ann Biol Clin (Paris); 1984; 42(1):21-3. PubMed ID: 6731952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X.
    Erskine JG; Walker ID; Davidson JF
    Clin Lab Haematol; 1982; 4(2):179-86. PubMed ID: 7116798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin.
    Rezaie AR; Yang L; Manithody C
    Biochemistry; 2004 Mar; 43(10):2898-905. PubMed ID: 15005625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood clotting diagnosis with chromogenic substrates].
    Róka L; Rasche H
    Internist (Berl); 1980 Apr; 21(4):189-94. PubMed ID: 6998907
    [No Abstract]   [Full Text] [Related]  

  • 16. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogenic assays for equine coagulation factors VII, VIII:C, IX, and X, and C1-esterase inhibitor.
    Topper MJ; Prasse KW
    Am J Vet Res; 1998 May; 59(5):538-41. PubMed ID: 9582952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coacute heparin: a new simple monotest for monitoring heparin treatment.
    Friberger P; Krig E; Eriksson-Skoog L; Svensson S; Isacson C
    Semin Thromb Hemost; 1993; 19 Suppl 1():86-9. PubMed ID: 8362270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The poor reliability of factor X chromogenic assays in coumarin treated patients.
    Girolami A; Sartori MT; Boeri G
    Thromb Haemost; 1992 Feb; 67(2):281. PubMed ID: 1621250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.